CDX 7.41% 12.5¢ cardiex limited

Ann: CardieX June 2020 Quarterly Activity Report, page-7

ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
  1. 6,052 Posts.
    lightbulb Created with Sketch. 1868
    There is no question that there are several possible trigger events that could occur in the next few months for this Company. If any one of them got ticked off, the current $27m mkt cap can easily double, but I think this has way more to run in the longer term. The well documented missteps of our CEO on HC did not help generate the right front for the Company - CEO's need to stay the heck away from stock forums.

    But despite this, I think there is very good buying to be had at these levels.

    Be curious to know if anyone knows how to track down the process for the approval or have any timelines for the Australian reimbursement process.

    The biggie though is wearable sensors and with a device already FDA approved, any further approval processes will be streamlined , as was mentioned somewhere in the Quarterly. The study results of the effects of COVID on blood pressure could also be a trigger event.

    Nov 21 is key for oppies exercise at 5c - they will need this money and I'm sure there is a focus on driving things forward to get the price beyond that mark in 15 months

    Changed sentiment - should have changed it earlier, as I bought a parcel today



 
watchlist Created with Sketch. Add CDX (ASX) to my watchlist
(20min delay)
Last
12.5¢
Change
-0.010(7.41%)
Mkt cap ! $36.77M
Open High Low Value Volume
14.5¢ 14.5¢ 12.5¢ $27.98K 206.2K

Buyers (Bids)

No. Vol. Price($)
2 92605 12.5¢
 

Sellers (Offers)

Price($) Vol. No.
13.0¢ 17750 1
View Market Depth
Last trade - 16.10pm 08/11/2024 (20 minute delay) ?
CDX (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.